Introduction
Although allogeneic hematopoietic stem cell transplantation (HSCT) is a highly effective treatment for leukemia, its therapeutic potential is counterbalanced by treatment-related toxicity, especially the development of graft-versus-host disease (GVHD) and relapse due to minimal residual leukemic cells remains, which are major complications and formidable obstacles [1] . Many patients relapse with or die of GVHD, even after transplantation. The use of immunosuppressors against GVHD is not conducive to the absolute depletion of residual leukemic cells. Therefore, the development of appropriate anticancer drugs remains an important goal [2] . Trans-Cinnamaldehyde (TCA), also known as cinnamaldehyde, is an active compound isolated from the stem bark of Cinnamomum cassia. The chemical structure of TCA is shown in Figure 1 . TCA can be applied as a flavorant, an agrichemical, an antimicrobial and in miscellaneous uses, such as a corrosion inhibitor for steel and other ferrous alloys in corrosive fluids. With the exception of being a skin irritant, TCA has low toxicity. Recent documented data showed TCA could induce the apoptosis of several human tumor cell lines, including human promyelocytic leukemia HL-60 cells [3, 4] . Interestingly, TCA has been shown to interfere with T cell activation through different mechanisms and could, therefore, have additive effects on the inhibition of T cell activation [5] . Activated T cells are well recognized as the first component of a [6] . Thus, TCA may be a promising drug for modulating the immune response and dealing with relapse and GVHD.
Cytokine-induced killer (CIK) cells, derived from the peripheral blood of normal donors or leukemia/lymphoma patients, are T cells with a characteristic immunophenotype of CD3 and CD56 double positivity. Data show that CIK cells exhibit potent anti-tumor activity in vitro and in vivo, they do not interfere with bone marrow engraftment in vivo and have little GVHD activity in several allogeneic models [7] . In this study, we first investigate the effects of TCA on the apoptosis of K562 leukemic cells and the effect of TCA on the cytotoxicity of CIK cells against K562 cells. Our aim is to provide evidence for the development of TCA as an anticancer drug to treat leukemia, even in patients after HSCT.
Materials and methods
Reagents TCA (C 9 H 8 O, molecular weight=132.16, purity≥95%) was obtained from Sinopharm Chemical Reagent Co Ltd, China. A 200 mmol/L solution of TCA was prepared in dimethyl sulfoxide (DMSO) and stored in aliquots at -20 °C until use. The final concentration of DMSO did not exceed 0.1% in any experiment. DMSO and propidium iodide (PI) were purchased from Sigma-Aldrich Inc, USA. Fetal bovine serum (FBS) and RPMI 1640 were purchased from Gibco-BRL Inc, USA. FicollHypaque (1.077 g/mL) was purchased from Haoyang Biological manufacture Co, China. Fluorescein isothiocyanate (FITC) labeled anti-CD3 antibody (CD3-FITC), phycoerythrin (PE) labeled anti-Fas (CD95) and anti-CD56 antibodies (CD95-PE, CD56-PE) were obtained from BD PharMingen, USA. The Annexin-V/PI Staining Kit was purchased from Bender Medsystems Inc, Austria. Carboxyfluorescein succinimidyl ester (CFSE) was purchased from Molecular Probes, USA. Anti-CD3 (Orthoclone OKT 3) was from Cilag GmbH, Germany. Interleukin-1β (IL-1β) and interleukin-2 (IL-2) were purchased from R&D Systems, Germany. Human recombinant interferon γ (IFN-γ) was purchased from Boehringer Mannheim, Germany.
Cell culture
The K562 cell line was obtained from the American Type Culture Collection, USA. Cells were cultured in complete medium (RPMI-1640 medium with 10% FBS containing 100 U/mL penicillin, 100 μg/mL streptomycin) at 37 °C in a 5% CO 2 humidified atmosphere. The medium was changed every 2 days. The experiments were performed on cells during their exponential phase of growth. Fas/CD95 expression analysis by flow cytometry After treatment with TCA for 4, 9, or 24 h, K562 cells were washed with PBS and incubated for 20 min on ice with PElabeled anti-Fas (CD95) antibody. Then, the cells were immediately analyzed by the flow cytometry.
Mitochondrial transmembrane potential (∆ψm) analysis by flow cytometry After treatment with TCA for 24 h, K562 cells were washed with PBS and incubated for 15 min at 37 °C with 0.5 mg/L Rho123, a fluorescent staining dye used to evaluate the change of ∆ψm. The cells were immediately analyzed by the flow cytometry.
Generation and immunophenotype identification of CIK cells CIK cells were generated under good manufacturing practice conditions as previously described [8] . First, peripheral blood samples from five healthy donors were collected after obtaining informed consent. Mononuclear cells were isolated by Ficoll-Hypaque gradient purification as per the manufacturer's instructions. Peripheral blood mononuclear cells (PBMNCs) were grown in complete culture medium at 37 °C in a 5% CO 2 humidified atmosphere. At day 0, IFN-γ was added to the cells at a final concentration of 1000 U/mL. After 24 h of incubation, 50 ng/mL of anti-CD3, 100 U/mL IL-1β and 300 U/ mL IL-2 were added. Cells were incubated and sub-cultured every third day in fresh complete medium containing IL-2 and anti-CD3 at 3×10 6 cells/mL. CIK cells were harvested on day +10. Immunophenotypic identification of the PBMNCs on day 0 and CIK cells on day +10 was performed by FACS flow cytometry (Becton Dickinson). The percentages of lymphocytes expressing CD3CD56 molecules were determined at each time point.
Cytotoxicity assay K562 cells were labeled with CFSE, a fluorescent live cellstaining dye, according to the original method described elsewhere and modified [9] . CFSE-labeled K562 cells were seeded at a density of 2×10 5 cells/mL into a flask in complete medium and pretreated with TCA at a final concentration of 120 or 180 µmol/L for 4 h. Following TCA exposure, the cells were reseeded in 24-well plates as the target cells (T) at a constant number of 60 000 cells after two washes with complete medium. CIK cells were added as effector cells (E) into target cell cultures at one of two E:T ratios (25:1 or 50:1). In parallel, target cells were incubated alone to measure basal lysis. For the continuous TCA treatment group, TCA at a final concentration of 120 or 180 μmol/L was added into corresponding cultures. All cells were incubated for another 5 h. Then, aliquots of freshly collected cells were centrifuged, washed in PBS and resuspended in PBS containing 25 μg/mL PI. After incubation for 20 min at room temperature in the dark, acquisition was performed without delay on a FACS flow cytometer. CFSE fluorescence and PI emission were detected using 
Statistical analysis
All data are expressed as means±standard deviations (SD). Statistical analysis was performed using SPSS12.0. Differences between repeated experiments with variable concentrations of TCA were computed using the Student's t test. P<0.05 was considered to be statistically significant. Figure  2) . The apoptosis rate after treatment with 120 or 180 μmol/L TCA was 18.63%±1.42% and 38.98%±2.74%, respectively. The spontaneous apoptosis rate was 3.56%±0.72% in K562 cells.
Results

TCA induced apoptosis in K562 cells
K562 cells were treated with 120 or 180 μmol/L TCA. At 4, 9, or 24 h, cells were harvested for apoptosis analysis. At 4 h, TCA did not significantly induce K562 cells apoptosis. At 9 h, 180 μmol/L TCA markedly induced K562 cells apoptosis (8.9%±1.23%). At 24 h, TCA significantly increased the percentage of apoptotic cells in a dose-dependent manner (
TCA upregulated Fas expression in K562 cells
Fas/CD95 was not universally expressed in K562 cells, as described previously [10] . Exposure of K562 cells to TCA resulted in the expression of Fas/CD95 in K562 cells in a timedependent fashion and a dose-dependent manner (Figure 3) . + subset of cells comprised just 1%−4.7% of the lymphocytes in the freshly isolated PBMNCs in the starting culture. On day +10, the CD3 + CD56 + subset of cells was significantly expanded in the range of 28% to 50%, with a median of 37%.
The cytotoxic effect of expanded CIK cells was verified by performing a cytotoxicity assay against the CFSE-labeled target K562 cells. The K562 cells in a 20:1 E:T ratio were not distinct in the ungated forward scatter (FSC)/side scatter (SSC) dot plot shown in Figure 4 . To quantitate specific lysis, flow cytometry analysis was performed in two steps: (1) selection of target cells on the SSC/CFSE dot plot, distinguishable from effector cells by their CFSE-positivity ( Figure 4B) ; and (2) determination of the percentage of target lysis, corresponding to the percentage of CFSE + PI + cells (sample lysis) in the presence of effectors at a given E:T ratio ( Figure 4C ). In parallel, basal lysis was quantified, corresponding to the percentage of dead K562 target cells in the absence of both CIK cells and TCA. The percentage of specific lysis for a given E:T ratio was calculated as follows:
Measurable cytotoxicity was observed at the effector:target ratio of 25:1 and 50:1, with a mean specific lysis rate of 34.84%±2.13% and 49.26%±3.22%, respectively ( Figure 5 ).
After the above experiments, we evaluated the combined effects of CIK cells and TCA on K562 cells. To exclude the influence of TCA alone on the K562 cells, we pretreated target Cell apoptotic pathways commonly include the Fas and mitochondrial-mediated apoptotic pathway [11] . The Fas receptor is the most intensely studied death receptor. Fas forms the death inducing signaling complex (DISC) upon ligand binding. Membrane-anchored Fas ligand trimer on the surface of an adjacent cell causes trimerization of the Fas receptor. The extrinsic Fas pathway is sufficient to induce complete apoptosis in certain cell types through DISC assembly and subsequent caspase-8 activation. It is well known that the Fas/Fas ligand (FasL) pathway is an alternative effector mechanism used by CIK cells to lyse their target cells [12, 13] . CIK cells synthesize FasL and CIK culture supernatants contain biologically active soluble FasL [14] . Cytotoxicity was blocked by the addition of anti-Fas mAb [15] . A subset of CIK cells may induce an advantageous Th1-dominance microenvironment, inducing tumor apoptosis through the Fas/FasL pathway causing antitumor cytotoxicity in vivo [16] . CIK cells are MHC-unrestricted cytotoxic lymphocytes with the characteristic CD3 + CD56 + phenotype. They are generated from peripheral blood lymphocytes and represent a rare subset of circulating lymphocytes (from 1% to 5% of peripheral blood lymphocytes) [17] . At maturity, CIK cells exhibit potent cytotoxicity against autologous acute myeloid leukemia (AML) targets, as well as against allogeneic myeloid leukemia cells, regardless of the HLA types of these targets. It has also been reported that CIK cells are cytolytic against CML cells, both in vitro and in the SCID mouse tumor model [18] . Donor generated CIK cells do not induce GVHD as observed for unfractionated donor splenocytes, and they prolong the survival of murine leukemia-bearing mice. Therefore, the use of CIK cells in immunotherapy to eradicate resistant residual tumor cells with limited toxicity against normal cells is very promising [19] . In the present study, TCA upregulated the expression of Fas, indicating the Fas/FasL pathway may be involved in apoptosis by TCA and in the enhanced cytotoxicity triggered by CIK cells.
TCA, a drug with immunomodulatory and antitumor characteristics, was shown to induce apoptosis of K562 cells by Fas and mitochondrial-mediated apoptotic pathway. TCA synergized the cytotoxic capability of CIK cells against K562 target cells, perhaps via the upregulation of Fas on the target cells. If the combination of CIK cells and TCA can be used clinically, they may synergistically act on malignant cells in a manner that is beneficial to patients.
Current treatment strategies in adult patients with AML lead to complete remission (CR) in 50%-80% of the patients. Additionally, more than 80% of childhood and 35% of adult acute lymphoblastic leukemia (ALL) patients are cured with modern chemotherapy supplemented with HSCT [20] . Despite major progress in treating hematologic malignancies, much work remains ahead. Some of these patients will eventually relapse due to the persistence of residual leukemic cells that escape the cytotoxic effects of therapy [21] . Occasionally, routine radiation and chemotherapy used to treat leukemia are both unable to eradicate the residual and metastatic leukemic cells. Thus, with the exception of graft-versus-leukemia (GVL) effect, there are not many treatment options available today to eradicate residual malignant cells. However, GVL effect is mediated by GVHD, a potentially dangerous and usually mortal condition often developed by patients following HSCT [22] . Therefore, it is necessary to develop new strategies to treat patients post-HSCT.
In conclusion, TCA has cytotoxic effects on human leukemia K562 cells by inducing apoptosis and synergizing the cytotoxicity of CIK to K562 cells. These properties of TCA may be beneficial in treatment of leukemia, even in post-HSCT patients.
